Literature DB >> 21334102

[Detection and molecular staging of bladder cancer using real-time RT-PCR for gelatinases (MMP-2, MMP-9) and TIMP-2 in peripheral blood].

J C Angulo1, A Ferruelo, J M Rodríguez-Barbero, C Núñez, F R de Fata, J González.   

Abstract

INTRODUCTION: Molecular staging of bladder cancer based on the detection of mRNA of urothelial specific genes in circulating cancer cells has been inconclusive. We analyze whether real-time RT-PCR evaluation of gelatinases (MMP-9, MMP-2) and TIMP-2 in peripheral blood to diagnose and characterize patients with bladder neoplasm. MATERIAL AND
METHOD: Total RNA is extracted from circulating blood cells in 42 individuals (11 healthy controls, 31 patients with bladder cancer of different stages) and real-time RT-PCR performed using specific primers for MMP-9, MMP-2, TIMP-2 and ribosomal 18S. The quantification values of mRNA are described as relative to 18S mRNA (ΔΔCt method) and the results are blindly compared with data obtained from histological diagnosis and clinical staging.
RESULTS: Normalized levels of MMP-9 and MMP-2 mRNA are higher in patients with cancer than controls (1.82±0.6-fold and 2.7±0.6-fold, respectively; P<.05). Patients with metastatic disease also have increased MMP-9, MMP-2 and TIMP-2 mRNA levels (9.6±0,20-fold, 5.22±0.26-fold and 1,97±0,22-fold, respectively; P<.05). MMP-9 and MMP-2 are also associated with advanced clinical stage and grade (P<.05). A ratio between variables that increases the ability to segregate patients with Ta, T1, T2-4M0 and T2-4M1 tumours is proposed.
CONCLUSIONS: Both non-invasive bladder tumor recognition and molecular staging of the disease is possible using real-time RT-PCR-based detection of gelatinases and TIMP-2 in peripheral blood. The ability to distinguish metastatic disease is higher for MMP-9 but MMP-2 discriminates better levels of tumour invasion. Further investigation in this field could yield promising results regarding molecular evaluation of bladder neoplasia.
Copyright © 2010 AEU. Published by Elsevier Espana. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21334102     DOI: 10.1016/j.acuro.2010.10.006

Source DB:  PubMed          Journal:  Actas Urol Esp        ISSN: 0210-4806            Impact factor:   0.994


  4 in total

1.  Role of serum and urine transforming growth factor beta 1, matrix metallopeptidase 9, tissue inhibitor of metalloproteinase 2, and nerve growth factor beta levels and serum neutrophil-to-lymphocyte ratio in predicting recurrence and progression risks in patients with primary non-muscle invasive bladder cancer.

Authors:  Özgür Efiloğlu; Banu İşbilen Başok; Turgay Turan; Tuncay Toprak; Bülent Erol; Turhan Çaşkurlu; Asıf Yıldırım
Journal:  Turk J Urol       Date:  2020-02-07

Review 2.  Diagnostic value of circulating tumor cell detection in bladder and urothelial cancer: systematic review and meta-analysis.

Authors:  Pavlos Msaouel; Michael Koutsilieris
Journal:  BMC Cancer       Date:  2011-08-04       Impact factor: 4.430

3.  Prognostic significance of plasma matrix metalloprotease-2 in pancreatic cancer patients.

Authors:  Nidhi Singh; Surabhi Gupta; Ravindra M Pandey; Peush Sahni; Shyam S Chauhan; Anoop Saraya
Journal:  Indian J Med Res       Date:  2017-09       Impact factor: 2.375

4.  Matrix Metalloproteinases and Bladder Cancer: What is New?

Authors:  O Rodriguez Faba; J Palou-Redorta; J M Fernández-Gómez; F Algaba; N Eiró; H Villavicencio; F J Vizoso
Journal:  ISRN Urol       Date:  2012-07-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.